Researchers looked at tissue samples from ovarian cancer patients. (sciencedaily.com)
«Niraparib significantly improves outcome of ovarian cancer patients in landmark trial.» (sciencedaily.com)
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study. (sciencedaily.com)